230 related articles for article (PubMed ID: 17495969)
1. Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta.
Yan H; Wang YC; Li D; Wang Y; Liu W; Wu YL; Chen GQ
Leukemia; 2007 Jul; 21(7):1488-95. PubMed ID: 17495969
[TBL] [Abstract][Full Text] [Related]
2. Arsenic trioxide and bortezomib interact synergistically to induce apoptosis in chronic myelogenous leukemia cells resistant to imatinib mesylate through Bcr/Abl‑dependent mechanisms.
Xu W; Wei W; Yu Q; Wu C; Ye C; Wu Y; Yan H
Mol Med Rep; 2014 Sep; 10(3):1519-24. PubMed ID: 24939418
[TBL] [Abstract][Full Text] [Related]
3. Bortezomid enhances the efficacy of lidamycin against human multiple myeloma cells.
Zhen YZ; Lin YJ; Liu XJ; Shang BY; Zhen YS
Anticancer Drugs; 2013 Jul; 24(6):609-16. PubMed ID: 23698252
[TBL] [Abstract][Full Text] [Related]
4. Sustained activation of c-jun-N-terminal kinase plays a critical role in arsenic trioxide-induced cell apoptosis in multiple myeloma cell lines.
Kajiguchi T; Yamamoto K; Iida S; Ueda R; Emi N; Naoe T
Cancer Sci; 2006 Jun; 97(6):540-5. PubMed ID: 16734734
[TBL] [Abstract][Full Text] [Related]
5. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
6. Synergistic apoptosis induction in leukemic cells by miR-15a/16-1 and arsenic trioxide.
Gao SM; Chen C; Wu J; Tan Y; Yu K; Xing CY; Ye A; Yin L; Jiang L
Biochem Biophys Res Commun; 2010 Dec; 403(2):203-8. PubMed ID: 21056550
[TBL] [Abstract][Full Text] [Related]
7. The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis.
Zhang QL; Wang L; Zhang YW; Jiang XX; Yang F; Wu WL; Janin A; Chen Z; Shen ZX; Chen SJ; Zhao WL
Leukemia; 2009 Aug; 23(8):1507-14. PubMed ID: 19282831
[TBL] [Abstract][Full Text] [Related]
8. ASK1 is activated by arsenic trioxide in leukemic cells through accumulation of reactive oxygen species and may play a negative role in induction of apoptosis.
Yan W; Arai A; Aoki M; Ichijo H; Miura O
Biochem Biophys Res Commun; 2007 Apr; 355(4):1038-44. PubMed ID: 17331470
[TBL] [Abstract][Full Text] [Related]
9. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.
Yu C; Rahmani M; Conrad D; Subler M; Dent P; Grant S
Blood; 2003 Nov; 102(10):3765-74. PubMed ID: 12893773
[TBL] [Abstract][Full Text] [Related]
10. Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders.
Canestraro M; Galimberti S; Savli H; Palumbo GA; Tibullo D; Nagy B; Guerrini F; Piaggi S; Cine N; Metelli MR; Petrini M
Cancer Genet Cytogenet; 2010 Jun; 199(2):110-20. PubMed ID: 20471514
[TBL] [Abstract][Full Text] [Related]
11. Rottlerin synergistically enhances imatinib-induced apoptosis of BCR/ABL-expressing cells through its mitochondrial uncoupling effect independent of protein kinase C-delta.
Kurosu T; Tsuji K; Kida A; Koyama T; Yamamoto M; Miura O
Oncogene; 2007 May; 26(21):2975-87. PubMed ID: 17130834
[TBL] [Abstract][Full Text] [Related]
12. [Synergistic effects of arsenic trioxide and proteasome inhibitor bortezomib on apoptosis induction in Raji cell line].
He Y; Yang JM; Wang JM; Zhou H; Lü SQ; Hu XX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):794-8. PubMed ID: 18718063
[TBL] [Abstract][Full Text] [Related]
13. Curcumin stimulates reactive oxygen species production and potentiates apoptosis induction by the antitumor drugs arsenic trioxide and lonidamine in human myeloid leukemia cell lines.
Sánchez Y; Simón GP; Calviño E; de Blas E; Aller P
J Pharmacol Exp Ther; 2010 Oct; 335(1):114-23. PubMed ID: 20605902
[TBL] [Abstract][Full Text] [Related]
14. Quercetin decreases intracellular GSH content and potentiates the apoptotic action of the antileukemic drug arsenic trioxide in human leukemia cell lines.
Ramos AM; Aller P
Biochem Pharmacol; 2008 May; 75(10):1912-23. PubMed ID: 18359480
[TBL] [Abstract][Full Text] [Related]
15. Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition.
Wen J; Feng Y; Huang W; Chen H; Liao B; Rice L; Preti HA; Kamble RT; Zu Y; Ballon DJ; Chang CC
Leuk Res; 2010 Jan; 34(1):85-92. PubMed ID: 19608275
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib and sphingosine kinase inhibitor interact synergistically to induces apoptosis in BCR/ABl+ cells sensitive and resistant to STI571 through down-regulation Mcl-1.
Li QF; Yan J; Zhang K; Yang YF; Xiao FJ; Wu CT; Wang H; Wang LS
Biochem Biophys Res Commun; 2011 Feb; 405(1):31-6. PubMed ID: 21195056
[TBL] [Abstract][Full Text] [Related]
17. The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib.
Yu C; Rahmani M; Dent P; Grant S
Exp Cell Res; 2004 May; 295(2):555-66. PubMed ID: 15093752
[TBL] [Abstract][Full Text] [Related]
18. Increased apoptotic efficacy of lonidamine plus arsenic trioxide combination in human leukemia cells. Reactive oxygen species generation and defensive protein kinase (MEK/ERK, Akt/mTOR) modulation.
Calviño E; Estañ MC; Simón GP; Sancho P; Boyano-Adánez Mdel C; de Blas E; Bréard J; Aller P
Biochem Pharmacol; 2011 Dec; 82(11):1619-29. PubMed ID: 21889928
[TBL] [Abstract][Full Text] [Related]
19. Role of cysteine 288 in nucleophosmin cytoplasmic mutations: sensitization to toxicity induced by arsenic trioxide and bortezomib.
Huang M; Thomas D; Li MX; Feng W; Chan SM; Majeti R; Mitchell BS
Leukemia; 2013 Oct; 27(10):1970-80. PubMed ID: 23877794
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways.
Yu C; Friday BB; Lai JP; Yang L; Sarkaria J; Kay NE; Carter CA; Roberts LR; Kaufmann SH; Adjei AA
Mol Cancer Ther; 2006 Sep; 5(9):2378-87. PubMed ID: 16985072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
